Navigation Links
Daniel J. Nevrivy, Ph.D., Biotech and Pharmaceutical Patent Attorney, Launches New Law Firm Aimed at Helping Clients Preserve Their Capital
Date:12/16/2008

Daniel J. Nevrivy, Ph.D., a Washington, D.C. patent attorney, today announces the formation of Nevrivy Patent Law Group P.L.L.C., a law firm focused on biotechnology and pharmaceutical patent law that aims to help businesses, universities and inventors protect their intellectual property (IP) and preserve their capital.

WASHINGTON (Business Wire EON) December 16, 2008 -- The credit crisis and economic downturn pose extraordinary challenges for many of the nation's leading innovative companies who now find themselves with limited access to dwindling pools of capital to fund their innovation and development needs. "These organizations are finding themselves in a difficult situation, because while they recognize that investments in IP can generate a lot of long term value down the road, they must preserve their capital today to stay in business long enough to reap those rewards. The limited access to capital is forcing companies to make difficult choices about what projects to develop and what to put on hold or abandon," according to Dr. Nevrivy. Research universities are also feeling the pinch, hampered by anticipated budget shortfalls and endowments that have been hard hit by the fall in the stock market.

The fees required to obtain patents and build a valuable portfolio, or identify and analyze competitor patents, can be a very costly and significant expense for many organizations. In addition, billing rates for patent attorneys have soared in recent years, due in large part to increases in salaries and other overhead costs that firms have tried to pass along to clients. "Many law firm cost structures which have been built up over the last several years are not really in sync in today's market with businesses' needs. Businesses are trying to get a better handle on managing their costs because they want to preserve their capital to further their innovation and development go
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. SCOLR Pharma, Inc. Announces Resignation of CEO Daniel O. Wilds
2. Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations
3. Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit
4. MaxLife Fund Corp. Appoints Mr. Dan Schmitt, Mr. Randy Delkus and Mr. Daniel E. Kahan to its Board of Directors
5. Daniel Corcoran named President of Anthem Blue Cross and Blue Shield in Maine
6. HealthSouth Finalizes Sale of Corporate Campus to Daniel Corporation
7. Hiemstra Appoints Daniel C. Rosenman as Vice President of Research & Development
8. Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
9. Statement by Daniel W. Jones, M.D., American Heart Association President on President Bushs FY 2009 Budget Proposal
10. Vincent Corso and Daniel Trush Win 2007 Avis We Try Harder Awards
11. MaxLife Fund Corp. appoints Daniel E. Kahan, to its Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Daniel J. Nevrivy, Ph.D., Biotech and Pharmaceutical Patent Attorney, Launches New Law Firm Aimed at Helping Clients Preserve Their Capital 
(Date:8/29/2014)... The University of Houston Graduate College of Social Work is ... $1.25 million grant from the National Institute of Drug Abuse ... the long-term use and health consequences of heroin use. Additionally, ... support future research endeavors. , Heroin use has ... from prescription pain medication abuse to the cheaper and more ...
(Date:8/29/2014)... Lincoln, R.I. (PRWEB) August 29, 2014 A home ... can crop up if unaddressed. That’s why Amica Insurance is sharing ... The National Safety Council suggests taking the following safety measures: , ... and disinfectants – in their original containers, and keep them away ... on a wall bracket near an exit. , Bathroom ...
(Date:8/29/2014)... well-studied neuroregenerative effect, stimulating neurite extension in ... vitro, and enhancing nerve regeneration following nerve ... of FK506 to stimulate nerve regeneration is ... failure and hypertension, and its considerable cost. ... with other drugs reportedly cause life-threatening infections. ...
(Date:8/29/2014)... As a chiropractic physician and medical doctor an ... direct connection between the condition of the feet and ... shoe inserts and orthotics weren’t satisfying my patients, I ... said. , Customizable to a user’s needs, the patent-pending ... in order to help prevent pain in the foot, ...
(Date:8/29/2014)... Aug. 29, 2014 (HealthDay News) -- The main ... the Middle East and North Africa originated in ... studied so-called community-acquired methicillin-resistant Staphylococcus aureus ... have not recently been hospitalized. These infections typically ... person-to-person contact or through touching contaminated objects such ...
Breaking Medicine News(10 mins):Health News:$1.25 million NIH grant to aid research on impact of heroin use 2Health News:Improve Home Safety with Tips from Amica Insurance 2Health News: European MRSA Originated in Sub-Saharan Africa, Study Finds 2
... (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova") today announced ... PLC and unconditionally retract the announcement made earlier this ... Jensen, Chief Science Officer of Bridge BioResearch PLC, will ... , , About GENova Biotherapeutics Inc. , ...
... MISSION VIEJO, Calif., Sept. 18 The Ensign Group, Inc. ... group of skilled nursing, rehabilitative care services and assisted living companies, ... cash dividend of $0.045 per share of Ensign common stock, payable ... of September 30, 2009. Ensign has been a dividend-paying company since ...
... - revenues increase by 21% over ... figures are in Canadian dollars unless otherwise noted), , ... Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today ... 30, 2009. , "We had a very successful year in ...
... HAYWARD, Calif., Sept. 18 Solta Medical, Inc. (Nasdaq: ... market, today announced that it will present at the Maxim Group ... the Grand Hyatt New York Hotel in New York, NY. ... September 29, 2009. Stephen J. Fanning, Chairman, President and Chief ...
... SAN CARLOS, Calif., Sept. 18 Nektar Therapeutics (Nasdaq: ... Global Life Sciences Conference in New York at the Grand Hyatt Hotel ... , The presentation will be accessible via a Webcast through ... Nektar website: http://www.nektar.com . This Webcast will be available ...
... be a nasal spray, followed shortly by injectable one: CDC ... doses of the H1N1 swine flu vaccine will start shipping ... U.S. health officials said Friday. , These first 3.4 million ... FluMist. , "There is a good antibody response to the ...
Cached Medicine News:Health News:Bioniche Reports Fiscal 2009 Year-End Results 2Health News:Bioniche Reports Fiscal 2009 Year-End Results 3Health News:Bioniche Reports Fiscal 2009 Year-End Results 4Health News:Bioniche Reports Fiscal 2009 Year-End Results 5Health News:Bioniche Reports Fiscal 2009 Year-End Results 6Health News:Bioniche Reports Fiscal 2009 Year-End Results 7Health News:Bioniche Reports Fiscal 2009 Year-End Results 8Health News:Bioniche Reports Fiscal 2009 Year-End Results 9Health News:Bioniche Reports Fiscal 2009 Year-End Results 10Health News:Bioniche Reports Fiscal 2009 Year-End Results 11Health News:Bioniche Reports Fiscal 2009 Year-End Results 12Health News:Bioniche Reports Fiscal 2009 Year-End Results 13Health News:Bioniche Reports Fiscal 2009 Year-End Results 14Health News:Bioniche Reports Fiscal 2009 Year-End Results 15Health News:Solta Medical to Present at the Maxim Group Growth Conference 2Health News:Nektar Therapeutics to Present at the UBS 2009 Global Life Sciences Conference in New York City 2Health News:1st Doses of Swine Flu Vaccine Set for Early October 2Health News:1st Doses of Swine Flu Vaccine Set for Early October 3Health News:1st Doses of Swine Flu Vaccine Set for Early October 4
(Date:8/28/2014)... NEW YORK , Aug. 28, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02343464/North-America-Laparoscopes-Market-Outlook-to-2020.html North ... GlobalData,s new report, "North America Laparoscopes Market ... the North America Laparoscopes market. The report provides ...
(Date:8/28/2014)... -- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – ... - http://photos.prnewswire.com/prnh/20140828/140879 ) The ... Poland " an essential source of information and ... and provides insights into the demographic, regulatory, reimbursement ... provides valuable insights into the trends and segmentation ...
(Date:8/28/2014)... , Aug. 28, 2014 Tianyin ... ), a pharmaceutical company that specializes in patented ... and active pharmaceutical ingredients (API) today updates the ... Qionglai Facility (QLF). The Company ... (GMP) dataset for China Food & Drug Administration,s ...
Breaking Medicine Technology:North America Laparoscopes Market Outlook to 2020 2North America Laparoscopes Market Outlook to 2020 3North America Laparoscopes Market Outlook to 2020 4North America Laparoscopes Market Outlook to 2020 5North America Laparoscopes Market Outlook to 2020 6North America Laparoscopes Market Outlook to 2020 7North America Laparoscopes Market Outlook to 2020 8North America Laparoscopes Market Outlook to 2020 9North America Laparoscopes Market Outlook to 2020 10North America Laparoscopes Market Outlook to 2020 11Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2
... Some of the world,s largest pharmaceutical firms announced this ... in order to slash costs and keep investors happy, exposing ... AstraZeneca were the first to announce further job cuts with ... has already seen an extraordinary amount of job cuts over ...
... Md., Feb. 29, 2012  MedImmune today announced that ... approved FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) for ... early in the second quarter of last year.  ... approved by the FDA. All other ...
Cached Medicine Technology:Job Cuts from Major Pharmaceutical Firms Results in Tougher Competition, Says Advance Recruitment 2MedImmune Announces FDA Approval of First Four-strain Flu Vaccine, FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) 2MedImmune Announces FDA Approval of First Four-strain Flu Vaccine, FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) 3
... These specialty Eraser instruments have been ... with the right tool for situations ... a series of 25 gauge intraocular, ... discrete treatment of target tissues for ...
... to over 2,000 medical clinics nation wide, ... in mind, ChartingPlus relies heavily on a ... to improve documentation quality and increase productivity ... medical content is specific to your medical ...
Transfer your exams to AltaPoint with our EMR Exam Word Lists. Document systems as normal and annotate exceptions to the systems in the exam. AltaPoint EMR is configured to allow a specialty to cust...
... Pro Software developed a touchscreen EHR and ... While a user can choose to use ... to maintain eye contact while recording encounter ... Pro EHR also runs on a pen ...
Medicine Products: